• Je něco špatně v tomto záznamu ?

Expert opinion on NSCLC small specimen biomarker testing - Part 2: Analysis, reporting, and quality assessment

F. Penault-Llorca, KM. Kerr, P. Garrido, E. Thunnissen, E. Dequeker, N. Normanno, SJ. Patton, J. Fairley, J. Kapp, D. de Ridder, A. Ryška, H. Moch

. 2022 ; 481 (3) : 351-366. [pub] 20220720

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024699
E-zdroje Online Plný text

NLK ProQuest Central od 2003-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2011-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 2003-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2003-01-01 do Před 1 rokem

Odkazy

PubMed 35857103
DOI 10.1007/s00428-022-03344-1
Knihovny.cz E-zdroje

The diagnostic work-up for non-small cell lung cancer (NSCLC) requires biomarker testing to guide therapy choices. This article is the second of a two-part series. In Part 1, we summarised evidence-based recommendations for obtaining and processing small specimen samples (i.e. pre-analytical steps) from patients with advanced NSCLC. Here, in Part 2, we summarise evidence-based recommendations relating to analytical steps of biomarker testing (and associated reporting and quality assessment) of small specimen samples in NSCLC. As the number of biomarkers for actionable (genetic) targets and approved targeted therapies continues to increase, simultaneous testing of multiple actionable oncogenic drivers using next-generation sequencing (NGS) becomes imperative, as set forth in European Society for Medical Oncology guidelines. This is particularly relevant in advanced NSCLC, where tissue specimens are typically limited and NGS may help avoid tissue exhaustion compared with sequential biomarker testing. Despite guideline recommendations, significant discrepancies in access to NGS persist across Europe, primarily due to reimbursement constraints. The use of increasingly complex testing methods also has implications for the reporting of results. Molecular testing reports should include clinical interpretation with additional commentary on sample adequacy as appropriate. Molecular tumour boards are recommended to facilitate the interpretation of complex genetic information arising from NGS, and to collaboratively determine the optimal treatment for patients with NSCLC. Finally, whichever testing modality is employed, it is essential that adequate internal and external validation and quality control measures are implemented.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024699
003      
CZ-PrNML
005      
20221031100330.0
007      
ta
008      
221017s2022 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00428-022-03344-1 $2 doi
035    __
$a (PubMed)35857103
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Penault-Llorca, Frédérique $u University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Clermont-Ferrand, France
245    10
$a Expert opinion on NSCLC small specimen biomarker testing - Part 2: Analysis, reporting, and quality assessment / $c F. Penault-Llorca, KM. Kerr, P. Garrido, E. Thunnissen, E. Dequeker, N. Normanno, SJ. Patton, J. Fairley, J. Kapp, D. de Ridder, A. Ryška, H. Moch
520    9_
$a The diagnostic work-up for non-small cell lung cancer (NSCLC) requires biomarker testing to guide therapy choices. This article is the second of a two-part series. In Part 1, we summarised evidence-based recommendations for obtaining and processing small specimen samples (i.e. pre-analytical steps) from patients with advanced NSCLC. Here, in Part 2, we summarise evidence-based recommendations relating to analytical steps of biomarker testing (and associated reporting and quality assessment) of small specimen samples in NSCLC. As the number of biomarkers for actionable (genetic) targets and approved targeted therapies continues to increase, simultaneous testing of multiple actionable oncogenic drivers using next-generation sequencing (NGS) becomes imperative, as set forth in European Society for Medical Oncology guidelines. This is particularly relevant in advanced NSCLC, where tissue specimens are typically limited and NGS may help avoid tissue exhaustion compared with sequential biomarker testing. Despite guideline recommendations, significant discrepancies in access to NGS persist across Europe, primarily due to reimbursement constraints. The use of increasingly complex testing methods also has implications for the reporting of results. Molecular testing reports should include clinical interpretation with additional commentary on sample adequacy as appropriate. Molecular tumour boards are recommended to facilitate the interpretation of complex genetic information arising from NGS, and to collaboratively determine the optimal treatment for patients with NSCLC. Finally, whichever testing modality is employed, it is essential that adequate internal and external validation and quality control measures are implemented.
650    _2
$a biologické markery $7 D015415
650    12
$a nemalobuněčný karcinom plic $x diagnóza $x genetika $x patologie $7 D002289
650    _2
$a znalecký posudek $7 D005104
650    _2
$a vysoce účinné nukleotidové sekvenování $x metody $7 D059014
650    _2
$a lidé $7 D006801
650    12
$a nádory plic $x diagnóza $x farmakoterapie $x genetika $7 D008175
650    _2
$a mutace $7 D009154
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Kerr, Keith M $u Department of Pathology, Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen, UK
700    1_
$a Garrido, Pilar $u Medical Oncology Department, Hospital Universitario Ramón Y Cajal, University of Alcalá, Madrid, Spain
700    1_
$a Thunnissen, Erik $u Amsterdam University Medical Center, VU Medical Center, Amsterdam, the Netherlands
700    1_
$a Dequeker, Elisabeth $u Department of Public Health, Biomedical Quality Assurance Research Unit, Campus Gasthuisberg, University Leuven, Leuven, Belgium
700    1_
$a Normanno, Nicola $u Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori "Fondazione Giovanni Pascale" IRCCS, Naples, Italy
700    1_
$a Patton, Simon J $u EMQN CIC, Manchester, UK
700    1_
$a Fairley, Jenni $u GenQA, Edinburgh, UK
700    1_
$a Kapp, Joshua $u Amgen (Europe) GmbH, Rotkreuz, Switzerland
700    1_
$a de Ridder, Daniëlle $u Amgen BV, Breda, the Netherlands
700    1_
$a Ryška, Aleš $u Department of Pathology, Charles University Medical Faculty Hospital, Hradec Králové, Czech Republic
700    1_
$a Moch, Holger $u Department of Pathology and Molecular Pathology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. holger.moch@usz.ch $1 https://orcid.org/http://orcid.org/0000000279862839
773    0_
$w MED00004660 $t Virchows Archiv $x 1432-2307 $g Roč. 481, č. 3 (2022), s. 351-366
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35857103 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100328 $b ABA008
999    __
$a ok $b bmc $g 1854438 $s 1175989
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 481 $c 3 $d 351-366 $e 20220720 $i 1432-2307 $m Virchows Archiv $n Virchows Arch $x MED00004660
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace